Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 5.02, 5.07, 9.01 · 8-K

Adial Pharmaceuticals, Inc

ADILNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 17, 2026, Adial Pharmaceuticals, Inc. (the “Company”) convened its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).…

Filed Sep 18, 2026Accepted Sep 18, 2026, 4:27 PM EDTCIK 1513525Accession 0001213900-26-101434
Share

Company context

We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Our investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (“AUD”). AD04 was recently investigated in a Phase 3 clinical trial, designated the ONWARD trial, for the potential treatment of AUD in subjects with certain target genotypes, which were identified using our companion diagnostic genetic test. Based on our analysis of the subgroup data from the ONWARD trial, we are now focused on completing the clinical development program for AD04 in the specified genetic subgroups to meet regulatory requirements primarily in the U.S. and secondarily in Europe/U.K.

Current securities

Historical securities (1)

Recent company filings

  1. DEFA14A filingSep 18, 2026
  2. DEFA14A filingSep 16, 2026
  3. Entry into a Material Definitive Agreement · Other EventsSep 16, 2026
  4. S-3 filingAug 28, 2026
  5. S-8 filingAug 28, 2026

Disclosure sections

Items 5.02, 5.07, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 17, 2026, Adial Pharmaceuticals, Inc. (the “Company”) convened its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). As discussed in additional detail in Item 5.07, below, at the 2026 Annual Meeting, the Company’s stockholders approved (i) Amendment No. 8 to the Company’s 2017 Equity Incentive Plan, as amended (the “2017 Plan”), to increase the number of shares of Company common stock, par value $0.001 per share (“Common Stock”), authorized for issuance thereunder (the “2017 Plan Amendment”), (ii) the Adial Pharmaceuticals, Inc. 2026 Equity Incentive Plan (the “2026 Plan”), and (iii) the Adial Pharmaceuticals, Inc. 2026 Employee Stock Purchase Plan (the “2026 ESPP”). Summaries of the material terms of each of the 2017 Plan, as amended by the 2017 Plan Amendment, the 2026 Plan and the 2026 ESPP are set forth under the headings “Proposal No. 9: The 2017 Plan Amendment Proposal,” “Proposal No. 10: The 2026 Plan Proposal” and “Proposal No. 11: The 2026 ESPP Proposal” contained in the Company’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting (the “Definitive Proxy Statement”), which the Company filed with the Securities and Exchange Commission (the “SEC”) on August 24, 2026, and are incorporated herein by reference. The summaries are qualified in their entirety by reference to the full text of the 2017 Plan Amendment, 2026 Plan and 2026 ESPP, copies of which are attached to this Current Report on Form 8-K as Exhibits 10.1, 10.2 and 10.3, respectively, and are incorporated herein by reference.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07. Submission of Matters to a Vote of Security Holders. As noted above, on September 17, 2026, the Company convened the 2026 Annual Meeting. Of the 2,625,890 shares of Common Stock outstanding and entitled to vote as of the record date for the 2026 Annual Meeting, 1,278,677 shares, or 48.7%, were present or represented by proxy at the 2026 Annual Meeting and, therefore, a quorum was present. Based on preliminary voting reports, all twelve of the proposals on the agenda for the 2026 Annual Meeting have received overwhelming support from the Company’s stockholders. However, because the Company has not yet received Nasdaq’s conditional approval of the Initial Listing Application that the Company submitted to Nasdaq in connection with certain of the proposals presented to the Company’s stockholders for approval at the 2026 Annual Meeting, the Company determined to only move forward with the vote on Proposals 1, 2, 7, 8, 9, 10, 11 and 12 and to adjourn the 2026 Annual Meeting, in part, with respect to the vote on Proposals 3, 4, 5 and 6, as discussed in additional detail below. Each of the proposals voted on, and to be voted on, at the 2026 Annual Meeting, including at the adjournment or adjournments thereof, are described in detail in the Definitive Proxy Statement. The final results of voting on Proposals 1, 2, 7, 8, 9, 10, 11 and 12 presented at the 2026 Annual Meeting on September 17, 2026 are as follows: Proposal 1 - Election of Directors The Company’s stockholders elected each of Cary J. Claiborne and Robertson H. Gilliland as a Class II director, to serve until the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, with the following votes: Name of Director Votes For Withheld Broker Non-Votes ───────────────────────────────────────────────────────────────────────────── Cary J. Claiborne 831,079 4,758 442,840 Robertson H. Gilliland 826,834 9,003 442,840 Notwithstanding the foregoing, as disclosed in the Definitive Proxy Statement, each of Mr. Claiborne and Mr. Gilliland is expected to resign as a director shortly after all of the proposals set forth in the Definitive Proxy Statement are approved by the Company’s stockholders. Proposal 2 - Ratification of CBIZ CPAs P.C. (f/k/a Marcum, LLP) as the Company’s independent registered public accounting firm for the year ending December 31, 2026 The Company’s stockholders ratified the appointment of CBIZ CPAs P.C. (f/k/a Marcum, LLP) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, based on the following votes: Votes For Votes Against Abstentions Broker Non-Votes ─────────────────────────────────────────────────────────────────────── 1,256,114 20,974 1,589 0 Proposal 7 - Approval of Amendment to Certificate of Incorporation to Increase Authorized Shares The Company’s stockholders approved an amendment to the Company’s certificate of incorporation, as amended, to increase the number of authorized shares of its Common Stock from 100,000,000 to 500,000,000, based on the following votes: Votes For Votes Against Abstentions Broker Non-Votes ─────────────────────────────────────────────────────────────────────── 1,239,968 37,210 1,499 0 Proposal 8 - 2025 Warrant Exercise Proposal The Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of up to an aggregate of 552,940 shares of Common Stock, upon the exercise of its Series F common stock purchase warrants issued in connection with its private placement offering that closed on November 28, 2025, based on the following votes: Votes For Votes Against Abstentions Broker Non-Votes ─────────────────────────────────────────────────────────────────────── 825,651 9,086 1,100 442,840 Proposal 9 - 2017 Plan Amendment Proposal The Company’s stockholders approved the 2017 Plan Amendment, based on the following votes: Votes For Votes Against Abstentions Broker Non-Votes ─────────────────────────────────────────────────────────────────────── 828,388 6,378 1,071 442,840 Proposal 10 - 2026 Plan Proposal The Company’s stockholders approved the 2026 Plan, based on the following votes: Votes For Votes Against Abstentions Broker Non-Votes ─────────────────────────────────────────────────────────────────────── 821,237 13,510 1,090 442,840 Proposal 11 - 2026 ESPP Proposal The Company’s stockholders approved the 2026 ESPP, based on the following votes: Votes For Votes Against Abstentions Broker Non-Votes ─────────────────────────────────────────────────────────────────────── 824,241 10,495 1,101 442,840 Proposal 12 - Adjournment Proposal The Company’s stockholders approved the proposal to adjourn the 2026 Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposals 3, 4, 5, 6, 7, 8, 9 10 and 11 (the “Adjournment Proposal”), based on the following votes: Votes For Votes Against Abstentions Broker Non-Votes ─────────────────────────────────────────────────────────────────────── 1,246,908 30,228 1,541 0 As noted above, although each of Proposals 3, 4, 5 and 6 received support well in excess of the votes required for approval, based on preliminary voting reports, the Company determined to exercise its authority under the Adjournment Proposal to adjourn the 2026 Annual Meeting solely with respect to Proposals 3, 4, 5 and 6 in order to provide the Company additional time to obtain the necessary Nasdaq approvals prior to holding the vote for those proposals. The polls remain open for Proposals 3, 4, 5 and 6. The adjourned meeting will reconvene on October 1, 2026 at 8:30 a.m. Eastern Time at the Company’s offices located at 650 Peter Jefferson Parkway, Suite 230, Charlottesville, Virginia 22911. The record date for the 2026 Annual Meeting, as adjourned, remains August 17, 2026. Stockholders who have already submitted proxies with votes on Proposals 3, 4, 5 and 6 do not need to take further action unless they wish to change their vote. Important Information This document may be deemed to be solicitation material in respect of the 2026 Annual Meeting. In connection with the 2026 Annual Meeting, the Definitive Proxy Statement filed with the SEC and a proxy card with respect to its solicitation of proxies for the 2026 Annual Meeting. BEFORE MAKING ANY VOTING DECISIONS, SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ADJOURNED MEETING. The definitive proxy statement has been mailed to stockholders who are entitled to vote at the 2026 Annual Meeting. No changes have been made in the proposals to be voted on by stockholders at the 2026 Annual Meeting. The Definitive Proxy Statement and any other materials filed by the Company with the SEC can be obtained free of charge at the SEC’s website at www.sec.gov. Participants in the Solicitation The Company and its directors and executive officers and other employees may be deemed to be participants in the solicitation of proxies in respect of the adjourned 2026 Annual Meeting.